

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1726R1P1	Serial No. 09/713,425	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Presta, L.		
				Filing Date 15 Nov 2000	Group 1644	
U.S. PATENT DOCUMENTS						
Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
<i>Joe</i>	*188 2005/0118174A1	02.06.05	Presta, L.	424	1441	
Examiner	<i>David A Saunders</i>			Date Considered <i>2/17/06</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	
		Atty Docket No. P1726R1P1	Serial No. 09/713,425
LIST OF DISCLOSURES CITED BY APPLICANT  (Use several sheets if necessary)		Applicant Presta, L.	
		Filing Date 15 Nov 2000	Group 1644
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>			
<i>sub</i>	189	Artandi et al., "Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3" <u>Proc. Natl. Acad. Sci. USA</u> 89(1):94-98 (Jan 1, 1992)	
Examiner <i>David A. Saunders</i>		Date Considered <i>2/17/05</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)					U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1726R1P1	Serial No. 09/713,425
					Applicant Presta, L.			
					Filing Date 15 Nov 2000	Group 1644		
U.S. PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date	
<i>David A. Saenger</i>	*190	2003/0190311	09.10.03	Dall'Acqua et al.	424	130,1		
	*191	2004/0191265	30.09.04	Schenerman et al.	424	184,1		
FOREIGN PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No	
<i>David A. Saenger</i>	192	WO 01/58957	16.08.01	PCT	—	—		
	193	WO 04/004662	15.01.04	PCT	—	—		
	194	WO 04/029207	08.04.04	PCT	—	—		
	195	WO 04/035752	29.04.04	PCT	—	—		
	196	WO 04/063351	29.07.04	PCT	—	—		
	197	WO 04/092219	28.10.04	PCT	—	—		
	198	WO 04/099249	18.11.04	PCT	—	—		
	199	WO 05/037867	28.04.05	PCT	—	—		
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)								
<i>David A. Saenger</i>	200	Eccles et al., "Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?" <u>Breast Cancer Research</u> 3(2):86-90 (2001)						
<i>David A. Saenger</i>	201	Niu and Chiu, "FDA perspective on peptide formulation and stability issues" <u>Journal of Pharmaceutical Sciences</u> 87(11):1331-1334 (Nov 1998)						
<i>David A. Saenger</i>	202	Tutt et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors" <u>Journal of Immunology</u> 161(6):3176-3185 (Sep 15, 1998)						
Examiner	<i>David A. Saenger</i>				Date Considered <i>2/17/06</i>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

*\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*